PCN236 A LANDMARK RESPONSE ANALYSIS TO DETERMINE COST-EFFECTIVENESS OF THIRD-LINE NIVOLUMAB MONOTHERAPY FOR SMALL CELL LUNG CANCER
Abstract
Authors
C. Smare K. Dave A. Juarez-Garcia N. Schoenherr P. Abraham J.R. Penrod D.R. Camidge Y. Yuan